It has been the focus of a global clinical development program involving over 20 clinical studies with more than 2,600 patients worldwide, of which over 1,600 have been treated with Kybella. In the pooled, pivotal Phase III clinical trials, 68.2 percent of patients responded to Kybella, compared to 20.5 percent of patients who responded to placebo, based on validated physician and patient measurements.